Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-01-18
Share capital
8 032 700,00 PLN
Activity description

Instytut Biotechnologii Surowic I Szczepionek Biom is a Polish pharmaceutical and biotechnology company that produces biological medicines, specialized probiotics, rehydration solutions, and in vitro microbiological diagnostic products. They manufacture a variety of vaccines, including a unique vaccine against Pseudomonas aeruginosa, and ensure high-quality standards through GMP practices. The company collaborates with partners from dozens of countries, providing support for registration, promotion, and distribution of their products.

Registered address
Al.sosnowa 8, 30-224 Kraków, Poland
Website
biomed.plWebsite active
Email
Email address current
Phone
Electronic delivery address
AE:PL-22282-36577-EFDFJ-26

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 40.63mMedianUSD 782.27kAverageUSD 24.03m
Net profit
This companyUSD 19.80mMedianUSD 7.91kAverageUSD 2.59m
Operating costs
This companyUSD 15.45mMedianUSD 723.93kAverageUSD 19.92m
Assets
This companyUSD 262.25mMedianUSD 800.34kAverageUSD 29.11m

Bank accounts

Registered as a VAT taxpayer on 1997-01-01. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$711.4K
Buildings and premises
$2.3M

MSiG notices

27 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
May 20, 2026Shareholders' meeting convened
May 21, 2025Shareholders' meeting convened
May 16, 2024Shareholders' meeting convened
May 15, 2023Shareholders' meeting convened
Jun 24, 2022Shareholders' meeting convened

Public aid

6 public aid cases recorded, with a total value of $3,257,419.

PurposeGross amount
Regional investment aid
$2.5M
Training aid
$2,904
Aid for research and development projects: experimental development
$518.0K

European Funds

ProjectEU co-financing
Automatyzacja i cyfryzacja procesu wytwarzania szczepionek krytycznych DTP, Clodivac, Tetana, DT, D, d i TyT, w celu wzmocnienia odporności łańcucha dostaw UE
$2.5M

Tenders

99 tenders recorded as contractor: 57 national ($451,971) and 42 EU ($44,239,912).

SubjectAmount
Dostawa leków różnych
–
WOFiTM/8/2026/PN Dostawa szczepionek w latach 2026-2028
–
Szczepionka błoniczo-tężcowo-krztuścowa (DTP), do szczepień obowiązkowych dzieci do 2 roku życia oraz na rezerwę określoną w rozporządzeniu epidemicznym. Części: 1-3; znak postępowania: ZZP.ZP.411.125.2026
–

Public sector contracts

Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss Biomed is the contractor in 39 public sector contracts, worth PLN 28.11m in total. They were signed with 28 public buyers. The largest number (2) were signed with Ministerstwo Zdrowia.

Public buyerValue
Wojewódzka Stacja Sanitarno-Epidemiologiczna w KatowicachPLN 87.70
Wojewódzka Stacja Sanitarno-Epidemiologiczna w GdańskuPLN 697.00
Uniwersytecki Szpital Kliniczny w RadomskuPLN 344.50
Powiatowa Stacja Sanitarno-Epidemiologiczna w BytomiuPLN 1,128
Wojewódzka Stacja Sanitarno-Epidemiologiczna w GdańskuPLN 274.80

Trademarks

Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss Biomed holds 5 active trademarks registered with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2023.

MarkProtected until
ORSONUDI(word)Nov 19, 2035
LANO GLOW(word)May 28, 2035
NUDICOL(word)Nov 8, 2034
DENUDIN(word)Nov 8, 2034
BRACELAN(word)Oct 17, 2033

Regulatory authorisations

AuthorityTypeStatus
Integrated permit Active

Authorized Representatives

Anna Flis – President of the Management Board
Barbara Łukawska – Attorney-in-fact (joint)
Tomasz Betlej – Attorney-in-fact (joint)
Elżbieta Waga – Attorney-in-fact (joint)

Manner of representation

Joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will and sign on behalf of the company.

Supervisory board

Przemysław Andrzej Krupiński – Supervisory Board Member
Maria Janina Pytlik – Supervisory Board Member
Robert Mrzygłód – Supervisory Board Member

Beneficial owners

Person

Change history

DateEvent
2012-11-13Share capital change
2009-12-23Name change
2005-07-21Name change
2004-11-09Share capital change
2003-08-19Name change

FAQ

Last updated: 2026-03-20